Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Sold by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. decreased its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 74.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,807 shares of the medical research company's stock after selling 5,258 shares during the period. Jefferies Financial Group Inc.'s holdings in Bio-Rad Laboratories were worth $594,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in BIO. Venturi Wealth Management LLC grew its stake in shares of Bio-Rad Laboratories by 2,175.0% during the fourth quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company's stock valued at $30,000 after acquiring an additional 87 shares in the last quarter. GeoWealth Management LLC lifted its stake in shares of Bio-Rad Laboratories by 342.9% in the fourth quarter. GeoWealth Management LLC now owns 93 shares of the medical research company's stock worth $31,000 after acquiring an additional 72 shares in the last quarter. Picton Mahoney Asset Management boosted its holdings in Bio-Rad Laboratories by 55.6% in the fourth quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company's stock valued at $32,000 after purchasing an additional 35 shares during the last quarter. Asset Planning Inc acquired a new stake in Bio-Rad Laboratories during the 4th quarter valued at approximately $33,000. Finally, UMB Bank n.a. grew its stake in Bio-Rad Laboratories by 41.6% during the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock valued at $36,000 after purchasing an additional 32 shares in the last quarter. Hedge funds and other institutional investors own 65.24% of the company's stock.

Bio-Rad Laboratories Stock Performance

Shares of NYSE BIO traded down $2.30 during trading on Thursday, reaching $225.68. The stock had a trading volume of 85,304 shares, compared to its average volume of 316,051. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48. The stock has a market cap of $6.14 billion, a PE ratio of -3.47 and a beta of 1.00. Bio-Rad Laboratories, Inc. has a one year low of $215.38 and a one year high of $387.99. The firm's 50 day moving average price is $242.89 and its two-hundred day moving average price is $296.43.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical research company reported $2.54 EPS for the quarter, topping analysts' consensus estimates of $1.73 by $0.81. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. The firm had revenue of $585.40 million during the quarter, compared to the consensus estimate of $573.01 million. During the same quarter in the previous year, the company posted $2.30 earnings per share. The firm's revenue was down 4.2% on a year-over-year basis. On average, research analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Citigroup cut their target price on Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Wall Street Zen lowered shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Monday, February 17th. UBS Group cut their price target on shares of Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Royal Bank of Canada decreased their price objective on shares of Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating for the company in a report on Friday, May 2nd. Finally, Wells Fargo & Company dropped their target price on shares of Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $327.40.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.